Filing Details
- Accession Number:
- 0001209191-15-074185
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2015-10-05 20:16:07
- Reporting Period:
- 2015-10-01
- Filing Date:
- 2015-10-05
- Accepted Time:
- 2015-10-05 20:16:07
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1334365 | Yuchun Lee | C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2015-10-01 | 1,333 | $57.27 | 1,541 | No | 4 | M | Direct | |
Common Stock | Disposition | 2015-10-01 | 200 | $102.80 | 1,341 | No | 4 | S | Direct | |
Common Stock | Disposition | 2015-10-01 | 700 | $104.79 | 641 | No | 4 | S | Direct | |
Common Stock | Disposition | 2015-10-01 | 225 | $105.79 | 416 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (right to buy) | Disposition | 2015-10-01 | 1,333 | $0.00 | 1,333 | $57.27 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
27,334 | 2022-09-13 | No | 4 | M | Direct |
Footnotes
- Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1.
- Open market sales reported on this line occurred at a weighted average price of $102.80 (range $102.66 to $102.94).
- Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of $104.79 (range $104.38 to $105.36).
- Open market sales reported on this line occurred at a weighted average price of $105.79 (range $105.74 to $105.85).
- The option vests in 16 quarterly installments from 09/14/2012.